Xatek, Inc

Xatek, Inc., based in Chagrin Falls, OH, has developed ClotChip, a groundbreaking technology that makes the clinical evaluation of whole-blood coagulation significantly more accessible at the point of care. The innovation harnesses dielectric spectroscopy to assess coagulation without the need for special reagents, allowing for a straightforward approach suited for various markets.

The ClotChip's user-friendly design aims to transform how clinicians evaluate and manage bleeding risks, eliminating the complexities associated with traditional global hemostasis assays that require extensive training and specialized equipment. Recognized for its potential, ClotChip received FDA breakthrough device designation in March 2020 and is currently undergoing clinical studies.

Generated from the website